Enanta is a clinical stage biotechnology company dedicated to creating oral drugs with an emphasis on indications in virology and immunology. Our story began in 1995 when we grew from humble beginnings to the company we are today — one that collaborated with AbbVie to discover two protease inhibitor compounds that were each developed and commercialized as part of an AbbVie combination regimen for chronic hepatitis C virus infection (glecaprevir in MAVYRET® and paritaprevir in VIEKIRA PAK®). We have also developed clinical candidates in nonalcoholic steatohepatitis, hepatitis B virus and SARS-CoV-2. Currently, our research and development programs are focused on respiratory syncytial virus and chronic spontaneous urticaria.
From our CEO
Enanta Pharmaceuticals is driven to develop best-in-class oral therapies that profoundly improve patients’ lives. We are focused on discovering novel drugs by leveraging proven methods grounded in medicinal chemistry, molecular biology and pharmacology. Through scientific excellence and imagination, we leverage our expertise in small molecule drugs to discover and develop groundbreaking medicines. Our vision is clear: we aim to transform the lives of patients with curative therapies.
Our previous success includes the discovery and development of two protease inhibitor compounds through our collaboration with AbbVie, which are sold as part of AbbVie’s combination regimens for chronic hepatitis C virus. These two regimens, which have been marketed under the trade names VIEKIRA PAK® and MAVYRET®, have helped cure over one million patients. We now work in other disease areas on treatments for patients where there is a significant high unmet need. Our areas of focus include virology and immunology.
At Enanta, we are working to have scientific innovation make a meaningful difference for patients suffering from serious viral infections and immunological diseases.
Jay R. Luly, Ph.D.
President, Chief Executive Officer and Director
Mission & Vision
Mission Through scientific excellence and imagination, we leverage our expertise in small molecule drugs to discover and develop groundbreaking medicines.
Vision To transform the lives of patients with curative therapies
Enanta Pharmaceuticals Founded
Yat Sun Or, Ph.D. Joins Enanta Pharmaceuticals as Chief Scientific Officer
Jay R. Luly, Ph.D. Joins Enanta Pharmaceuticals as President and Chief Executive Officer
Enanta Pharmaceuticals Licenses EDP-420 for the Treatment of Community-Acquired Pneumonia to Shionogi
Enanta Pharmaceuticals and Chiron Announce Collaboration to Develop Hepatitis C Protease Inhibitors
Enanta Pharmaceuticals and Abbott Announce Agreement to Develop Protease Inhibitors for Hepatitis C Virus
Enanta’s Lead HCV Protease Inhibitor Compound ABT-450 Advances into Phase 3 Clinical Trial in a Triple Combination Treatment with Abbott’s NS5A Inhibitor
Enanta Pharmaceuticals Enters into Strategic Collaboration with Novartis to Advance Enanta’s NS5A Inhibitor Candidate for Hepatitis C Virus
Enanta Pharmaceuticals Launches Initial Public Offering
Enanta Pharmaceuticals and AbbVie Announce FDA Approves VIEKIRA PAK®, AbbVie’s Combination Drug for the Treatment of Chronic Genotype 1 Hepatitis C Virus
Enanta Pharmaceuticals and AbbVie Announce European Commission Grants Marketing Authorization for AbbVie’s VIEKIRAX™
Enanta Pharmaceuticals Announces Positive Phase 1 Clinical Study of EDP-305, its Lead FXR Agonist for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Enanta Pharmaceuticals Announces that AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Received Approval in U.S., E.U. and Japan for the 8-Week Treatment Most Major Genotypes of Chronic Hepatitis C Infection
Enanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus
Enanta Pharmaceuticals Announces Topline Results Showing EDP-938 Achieved its Primary and Secondary Endpoints in a Phase 2a Human Challenge Study in Healthy Adults Infected with Respiratory Syncytial Virus
Enanta Adds Hepatitis B Virus to its Pipeline with the Initiation of Phase 1 Clinical Study of Core Inhibitor EDP-514
Enanta Pharmaceuticals’ HCV Collaboration Partner AbbVie Receives Marketing Authorization from the European Commission to Shorten MAVIRET® (glecaprevir/pibrentasvir) to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis
Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19
Enanta Pharmaceuticals Announces Positive Data from Phase 1 Study of EDP-514 in Nucleos(t)ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection
Enanta Pharmaceuticals Announces Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus Core Inhibitor, in Viremic Chronic HBV Patients
Enanta Pharmaceuticals Adds COVID-19 to its Pipeline with the Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
Enanta Pharmaceuticals Initiates RSVPEDs, a Phase 2 Clinical Study of EDP-938 in Pediatric Patients with Respiratory Syncytial Virus
Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19
Enanta Pharmaceuticals Initiates RSVHR, a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19
Enanta Celebrates 10 Year IPO Anniversary with NASDAQ Bell Ringing
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus